Pharmathen has successfully passed an FDA audit of its Sapes-based oral solids and injectables facility. This certification will allow Pharmathen to produce and market its products in the USA, which is the largest pharmaceuticals market globally. The US market covers 40% of the world drug market, with an annual turnover of 293 billion €.
Pharmathen has developed a portfolio of innovative products that will accelerate its growth in the US and globally. Notably, Pharmathen is one of the few companies worldwide that develop injectable healthcare products with sustained-release based on the Long Acting Injectable (LAI) technology. The development of the LAI technology has made Pharmathen a leading force among the top organizations that head research developments worldwide, lending it a significant competitive advantage through the innovative products and technologies it makes available throughout the world.
Pharmathen invests systematically and consistently in research and this focused decision has resulted in becoming a reference point in the global pharmaceutical market. Currently, Pharmathen exports its products in more than 80 countries with more than 8500 Marketing Authorizations worldwide and has created strong partnerships with all major companies. The annual turnover from the exports of Pharmathen accounts to 1% of the total exports of Greece.